Pathogenesis of Hematologic Malignancies

OHSU Knight Cancer Institute

Status: Invitation-only

Conditions: Acute Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Lymphoproliferative Disorders

Treatments: Procedure: blood draw, bone marrow procedure, or tissue biopsy

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01728402

IRB00004422

5R21CA159265 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The cause of blood and bone marrow cancers is poorly understood; however, most research focuses on how cancer cells grow and develop. Because the causes of these cancers are unknown, current treatments may be unnecessarily harsh and often do not provide a cure. Identifying the causes of blood cancers would allow for the development of treatments that are more likely to provide a cure. To find the causes of blood and bone marrow cancers, we will look for specific cancer cell abnormalities that are responsible for cancer cell growth. We will then look to see if drugs that can reverse these abnormalities can kill cancer cells.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 1+ year old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
• Male or female of all ages
• Willing and able to sign informed consent
• Willing guardian consent for participants under 18 years of age

Exclusion criteria

• No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)

Trial design

5,000 participants in 1 patient group

Blood Draw

Treatment:

Procedure: blood draw, bone marrow procedure, or tissue biopsy